88,112 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Purchased by American Century Companies Inc.

American Century Companies Inc. purchased a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 88,112 shares of the company's stock, valued at approximately $319,000. American Century Companies Inc. owned approximately 0.10% of Atyr PHARMA at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ATYR. Kingswood Wealth Advisors LLC purchased a new position in Atyr PHARMA in the 4th quarter worth approximately $170,000. Charles Schwab Investment Management Inc. purchased a new position in Atyr PHARMA during the fourth quarter worth approximately $144,000. D.A. Davidson & CO. purchased a new position in Atyr PHARMA during the fourth quarter worth approximately $141,000. Farther Finance Advisors LLC purchased a new stake in Atyr PHARMA in the 4th quarter valued at $88,000. Finally, JPMorgan Chase & Co. grew its holdings in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Trading Down 0.7 %

Shares of ATYR traded down $0.02 during trading on Tuesday, reaching $2.99. 818,860 shares of the company traded hands, compared to its average volume of 894,401. The stock has a 50-day simple moving average of $3.44 and a 200-day simple moving average of $3.28. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.66. The stock has a market cap of $265.69 million, a PE ratio of -3.18 and a beta of 0.95.

Remove Ads

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Leerink Partners started coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald assumed coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an "overweight" rating on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.